TY - JOUR
T1 - Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites
AU - Salerno, Francesco
AU - Lorenzano, Elettra
AU - Maggi, Alessandra
AU - Badalamenti, Salvatore
AU - Minuz, Piero
AU - Degan, Maurizio
AU - Chinea, Benito
AU - Scotti, Aurelio
PY - 1993
Y1 - 1993
N2 - Imidazole-salicylate is a non-steroidal anti-inflammatory drug with limited inhibitory effects on prostaglandin synthesis. The renal effects of this drug were investigated by a double-blind corss-over study in 10 patients with cirrhosis and ascites. Two therapeutic doses of imidazole-salicylate (750 mg each) were given at midnight and 08:00 h and 80 mg of furosemide were injected intravenously at 09:00 h. The same procedure was followed on another day but a placebo replaced imidazole-salicylate. Renal function (creatinine clearance, free water and electrolyte excretions) and urinary excretion of prostaglandin E, 6-keto-prostaglandin F1α and thromboxane B2 were evaluated for 8 h after the first dose of the drug and for 2 h after furosemide injection. Platelet thromboxane production was also determined 9 h after the first administration of drug or placebo. Imidazole-salicylate did not affect renal function or inhibit kidney prostanoid production either under basal conditions or after the stimulating effect of furosemide. On the contrary, imidazole-salicylate significantly inhibited platelet thromboxane production (45.8 ± 9 vs. 69.4 ± 7.5 ng/ml, P <0.05). These results suggest that imidazole-salicylate is an anti-inflammatory drug that can be given to patients with decompensated cirrhosis without risk of inhibiting kidney prostaglandin synthesis or the renal response to furosemide.
AB - Imidazole-salicylate is a non-steroidal anti-inflammatory drug with limited inhibitory effects on prostaglandin synthesis. The renal effects of this drug were investigated by a double-blind corss-over study in 10 patients with cirrhosis and ascites. Two therapeutic doses of imidazole-salicylate (750 mg each) were given at midnight and 08:00 h and 80 mg of furosemide were injected intravenously at 09:00 h. The same procedure was followed on another day but a placebo replaced imidazole-salicylate. Renal function (creatinine clearance, free water and electrolyte excretions) and urinary excretion of prostaglandin E, 6-keto-prostaglandin F1α and thromboxane B2 were evaluated for 8 h after the first dose of the drug and for 2 h after furosemide injection. Platelet thromboxane production was also determined 9 h after the first administration of drug or placebo. Imidazole-salicylate did not affect renal function or inhibit kidney prostanoid production either under basal conditions or after the stimulating effect of furosemide. On the contrary, imidazole-salicylate significantly inhibited platelet thromboxane production (45.8 ± 9 vs. 69.4 ± 7.5 ng/ml, P <0.05). These results suggest that imidazole-salicylate is an anti-inflammatory drug that can be given to patients with decompensated cirrhosis without risk of inhibiting kidney prostaglandin synthesis or the renal response to furosemide.
KW - Diuretics
KW - Non-steroidal anti-inflammatory drugs
KW - Prostaglandins
KW - Thromboxane
UR - http://www.scopus.com/inward/record.url?scp=0027501873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027501873&partnerID=8YFLogxK
U2 - 10.1016/S0168-8278(05)80583-5
DO - 10.1016/S0168-8278(05)80583-5
M3 - Article
C2 - 8301062
AN - SCOPUS:0027501873
VL - 19
SP - 279
EP - 284
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 2
ER -